Mymetics Corp (MYMX)

[Work Harder]

Supplemental Digital Content for

Mucosal AIDS virus transmission is enhanced by antiviral IgG isolated early in infection

*Correspondence to: [e-mail]

Current address: S.K.L.: University of Texas MD Anderson Cancer Center, Houston, TX

A.A.: Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA

Fig. S3. A3R5.7 cell line-based neutralization assay of the two macaques selected as IgG donors for the enSHIVIG prep. Polyclonal IgG was purified from sera of donor macaques at the time points post-infection indicated. The macaques were in the early stages of SHIV-2873Nip [2] infection. (a and b) Neutralization assays were performed using A3R5.7 cells with the reporter virus NL-LucR.1157ipd3N4 (see Fig. S1 legend). The assay was terminated after 48 h and bioluminescence was read.

Fig. S4. A3R5.7 cell line-based neutralization assay. Polyclonal IgG was purified from donor macaques at the time points post-infection indicated. The macaques were in the early stages of infection with SHIV-2873Nip [2]. (a-f) Neutralization assays were performed using A3R5.7 cells with the reporter virus NL-LucR.1157ipd3N4 as described in the legend for Fig. S3

Fig. S6. Pharmacokinetic study. Three rhesus macaques were treated intravenously (i.v.) with different doses of enSHIVIG. Serum samples were collected, and enSHIVIG concentrations were measured by ELISA binding to HIV-C gp120. IgG was isolated from serum samples and C’-ADE assays were performed. Negative neutralization indicates enhancement. The assays were performed at 24 h after enSHIVIG administration, a time point chosen based upon our earlier data [5]; *for animal 33174, only insufficient IgG amounts could be recovered from the 24 h time point; the value given shows C’-ADE at 12 h post treatment.